Mr. Johnson will serve as president and chief executive officer of Dendreon until August 15, 2014. Mr. Johnson served as a member of Dendreon's Board of Directors from August 2011 to June 2014. Prior to joining Dendreon, Mr. Johnson was the chief executive officer and a member of the Board of Directors of Savient Pharmaceuticals, Inc., from January 2011 to January 2012. Prior to that position, Mr. Johnson served as president of Eli Lilly & Company's Oncology Unit, following the company's 2008 acquisition of Imclone Systems, Inc., where he served as chief executive officer. Prior to joining Imclone, he served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Prior to assuming that role, Mr. Johnson held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp., and Pfizer, Inc. Mr. Johnson is the former chairman of Tranzyme Pharma, Inc., and is currently a member of the Board of Directors for Cempra Pharmaceuticals, Inc., Histogenics and Portola Pharmaceuticals, Inc. He also serves as a member of the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).